EBV Inhibitor

VK-2019 is an orally bioavailable selective inhibitor of EBNA1. By binding to the protein-DNA interface to interfere with the recruitment and anchoring of the viral DNA replication machinery, VK-2019 effectively blocks the replication and proliferation of EBV in latently infected cells. VK-2019 reduces the copy number and gene expression level of Epstein-Barr virus in tumor cells, decreases the number of EBER-positive cells, and exhibits significant antiviral, immunomodulatory and antiproliferative activities. VK-2019 successfully inhibits tumor growth in EBV-dependent xenograft models. VK-2019 has favorable systemic exposure and acceptable safety profiles, and is widely used in research on advanced nasopharyngeal carcinoma and various EBV-associated cancers.

Vidarabine (Ara-A) is a nucleoside antibiotic isolated from Streptomyces, and a metabolite of Vidarabine phosphate (HY-B0277A). Vidarabine selectively inhibits viral DNA polymerase and cellular ribonucleotide reductase, thereby blocking viral replication. Vidarabine phosphate also exhibits antifungal activity, induces late-stage cellular apoptosis, and causes cell cycle arrest. Vidarabine phosphate can be used in research related to severe chronic active Epstein-Barr virus (EBV) infection, herpes infection, and candidiasis.

Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen (EBV-EA) activation with an IC₅₀ of 290 mol ratio/32 pmol TPA. Methyl lucidenate D exerts potential anti-tumor promoting activity by inhibiting TPA-induced EBV-EA activation and maintains major Raji cell survival (70%) at effective concentrations. Methyl lucidenate D can be used in the field of cancer chemoprevention.

Narcissin (Narcissoside), a flavonol glycoside, exhibits evident scavenging activity against both authentic ONOO^- and SIN-1-derived ONOO^- with IC₅₀s of 3.5 and 9.6 μM, respectively.

VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research.

Vidarabine phosphate (ara-AMP; ara-A 5'-monophosphate) is a purine nucleoside antiviral agent and a prodrug of Vidarabine (HY-B0277). Vidarabine phosphate is rapidly converted into the antiviral active Vidarabine in vivo, which selectively inhibits viral DNA polymerase and cellular ribonucleotide reductase, thereby blocking viral replication. Vidarabine phosphate also exhibits antifungal activity, induces late-stage cellular apoptosis, and causes cell cycle arrest. Vidarabine phosphate can be used in research related to severe chronic active Epstein-Barr virus (EBV) infection, herpes infection, and candidiasis.

Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.

GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes.

EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein.

L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM.

Vidarabine monohydrate is a Purine nucleoside derivative and Antiviral agent. The triphosphate derivative of Vidarabine monohydrate competitively inhibits DNA polymerase, incorporates into the terminus of elongating DNA molecules, and interferes with the early steps of viral DNA synthesis. Vidarabine monohydrate inhibits the replication of herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus and vaccinia virus, reduces viral shedding, and accelerates skin healing. Vidarabine monohydrate is metabolized to arabinosyl hypoxanthine, causes minimal impairment of corneal wound healing in rabbit models, and is associated with recurrence of herpes simplex encephalitis. Vidarabine monohydrate can be used in the research of herpetic keratoconjunctivitis, herpes simplex encephalitis, herpetic uveitis, and chronic active hepatitis associated with hepatitis B virus.

DNA polymerase-IN-6 formic is an antiviral agent and a DNA polymerase inhibitor. DNA polymerase-IN-6 formic inhibits the replication of HCMV, HSV-1, HSV-2 and EBV. DNA polymerase-IN-6 formic exhibits low cytotoxicity in mammalian cells. DNA polymerase-IN-6 formic can be used in research related to viral infections.

Fiacitabine (NSC 382097; FIAC; FOAC) is a potent and highly selective anti-herpesvirus agent. Fiacitabine acts as an inhibitor of HSV DNA polymerase, with a K_i of 0.26 μM for HSV-1 and 0.42 μM for HSV-2, respectively. Fiacitabine can be efficiently phosphorylated by thymidine kinase encoded by the virus itself to generate FIACTP, an active triphosphate metabolite. Fiacitabine is applicable to research related to herpesvirus infections.

Lobucavir (BMS-180194; SQ 34514)，a nucleoside analogue，is an antiviral agent. Lobucavir shows a broad spectrum of activity against HBV，HIV/AIDS，and α，β，and γ herpes viruses including CMV，herpes-simplex，varicella-zoster，and Epstein-Barr virus.

α-Cembrenediol is a potent inhibitor of EBV.α-Cembrenediol inhibits the early antigen of the Epstein-Bar virus. α-Cembrenediol also has anti-tumour activity.

DNA polymerase-IN-6 is an antiviral agent and a DNA polymerase inhibitor. DNA polymerase-IN-6 inhibits the replication of HCMV, HSV-1, HSV-2 and EBV. DNA polymerase-IN-6 exhibits low cytotoxicity in mammalian cells. DNA polymerase-IN-6 can be used in research related to viral infections.

Cabenoside D (compound 8) is a triterpenoid glycoside, which can be isolated from the methanol extract of lichen root. Cabenoside D shows anti-inflammatory activity and inhibits inflammation induced by 12-O-tetracylacyl hormone-13-acetate (TPA) in mice. Cabenoside D also inhibits TPA-induced Epstein-Barr virus (EBV) early antigen (EBV-EA) activation.

Vidarabine phosphate (ara-AMP; ara-A 5'-monophosphate) (Standard) is the analytical standard of Vidarabine phosphate. This product is intended for research and analytical applications. Vidarabine phosphate is a purine nucleoside antiviral agent and a prodrug of Vidarabine (HY-B0277). Vidarabine phosphate is rapidly converted into the antiviral active Vidarabine in vivo, which selectively inhibits viral DNA polymerase and cellular ribonucleotide reductase, thereby blocking viral replication. Vidarabine phosphate also exhibits antifungal activity, induces late-stage cellular apoptosis, and causes cell cycle arrest. Vidarabine phosphate can be used in research related to severe chronic active Epstein-Barr virus (EBV) infection, herpes infection, and candidiasis.

11-Oxomogroside II A1 (compound 7) is an oxidized cucurbitin. It can be isolated from the ethanol extract of Rohanberry fruit. 11-Oxomogroside II A1 inhibits the activation of Epstein-Barr virus (EBV) early antigen (EBV-EA) induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). 11-Oxomogroside II A1 also weakly inhibits the activation of (±)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.

YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence.